Abbie Lennox

Abbie Lennox was named Executive Vice President and Chief Scientific Officer in January 2025. Ms. Lennox joins Perrigo from Bayer where she served as Executive Board Member and Chief Trust and Science Officer, responsible for leading the regulatory, medical affairs, safety, and quality teams. She led multiple innovation launches – both product and claim-based – across product categories in cardio, digestive health, allergy, cough, cold, pain, dermatology, women's health, VMS, and Rx to OTC switches in the U.S. and the rest of the world. Specifically, Ms. Lennox provided scientific leadership for the U.S. Rx-to-OTC switch for Astepro®, emphasizing consumer-centric claims supported by robust medical insights. She also led the introduction of Rennie Gum, the first European OTC chewing gum for digestive health, navigating rigorous clinical and registration requirements while prioritizing consumer experience. Prior to her time at Bayer, she served in regulatory affairs leadership roles with Reckitt Benckiser, where she advanced the company’s regulatory approach to pipeline delivery across multiple health and wellness brands. Ms. Lennox holds a First Class BSc (Honors) degree in Biomedical Science and Chemistry from De Montfort University.